Search
Close this search box.
Trending now:  
Cardiac Shockwave Therapy: A Promising Treatment for Ischemic Heart Failure
The Evolution of Cardiovascular Magnetic Resonance: A 50-Year Journey
Vessel-Level Coronary Atherosclerotic Plaque Activity Predicts Myocardial Infarction Risk
DanGer Shock: Microaxial Flow Pump versus Standard Care in Infarct-Related Cardiogenic Shock
EuroPCR 2024 Highlights

Content for healthcare professionals only

News |

DanGer Shock: Microaxial Flow Pump versus Standard Care in Infarct-Related Cardiogenic Shock

04 Jun 2024

The DanShock trial (NCT01633502) assessed the efficacy of the Impella CP ventricular assist device in reducing mortality following myocardial infarction (MI). The Impella CP is a catheter-based axial flow pump that directly channels blood from the left ventricle into the circulation, delivering 3.5L/min (approximately 75% of normal cardiac output). Investigators randomized 360 patients to receive either a microaxial flow pump plus standard of care (SOC) (n=179) or SOC alone (n=176). The primary endpoint was all-cause mortality at 180 days. In the microaxial-flow-pump + SOC group, 82 patients (45.8%) died from any cause, compared to 103 patients (58.5%) in the SOC alone group, yielding a hazard ratio (HR) of 0.74 (confidence interval [CI] 0.55 to 0.99; P=0.04).

For more cardiology research news join our newsletter or follow us on TwitterFacebookLinkedIn or Instagram.

Share:

Related Topics

Related Articles